Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4*

Cytochrome P450 (P450) 3A4, the major catalyst involved in human drug oxidation, displays substrate- and reaction-dependent homotropic and heterotropic cooperative behavior. Although several models have been proposed, these mainly rely on steady-state kinetics and do not provide information on the contribution of the individual steps of P450 catalytic cycle to the observed cooperativity. In this work, we focused on the kinetics of substrate binding, and the fluorescent properties of bromocriptine and α-naphthoflavone allowed analysis of an initial ligand-P450 3A4 interaction that does not cause a perturbation of the heme spectrum. The binding stoichiometry for bromocriptine was determined to be unity using isothermal titration calorimetry and equilibrium dialysis methods, suggesting that the ligand bound to the peripheral site during the initial encounter dissociates subsequently. A three-step substrate binding model is proposed, based on absorbance and fluorescence stopped-flow kinetic data and equilibrium binding data obtained with bromocriptine, and evaluated using kinetic modeling. The results are consistent with the substrate molecule binding at a site peripheral to the active site and subsequently moving toward the active site to bind to the heme and resulting in a low to high spin iron shift. The last step is attributed to a conformational change in the enzyme active site. The later steps of binding were shown to have rate constants comparable with the subsequent steps of the catalytic cycle. The P450 3A4 binding process is more complex than a two-state system, and the overlap of rates of some of the events with subsequent steps is proposed to underlie the observed cooperativity.

[1]  A. P. Koley,et al.  Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. , 1996, Biochimie.

[2]  H. Yamazaki,et al.  Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. , 1995, Biochemistry.

[3]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[4]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[5]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[6]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[7]  C. Williams,et al.  A method for titrating oxygen-sensitive organic redox systems with reducing agents in solution. , 1969, Analytical biochemistry.

[8]  A. P. Koley,et al.  Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.

[9]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[10]  M. Delaforge,et al.  High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. , 1994, European Journal of Biochemistry.

[11]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[12]  S. Sligar,et al.  Twenty-five Years of P450cam Research , 1995 .

[13]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[14]  Ann-Charlotte Egnell,et al.  Predictive Models of CYP3A4 Heteroactivation: In Vitro-in Vivo Scaling and Pharmacophore Modeling , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  F. Guengerich,et al.  Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.

[16]  S. Sligar,et al.  Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. , 2004, Archives of biochemistry and biophysics.

[17]  W. Atkins,et al.  The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. , 2005, Biochemistry.

[18]  Smita S. Patel,et al.  Kinetic analysis of macromolecules : a practical approach , 2003 .

[19]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[20]  H. Yamazaki,et al.  Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4 , 1996, The Journal of Biological Chemistry.

[21]  R. Estabrook,et al.  Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.

[22]  L. Wienkers,et al.  Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. , 2002, Journal of the American Chemical Society.

[23]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[24]  M. Godejohann,et al.  Testosterone 1β‐hydroxylation by human cytochrome P450 3A4 , 2004 .

[25]  A. Fersht Structure and mechanism in protein science , 1998 .

[26]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[27]  F. Guengerich,et al.  Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. , 2004, Biochemistry.

[28]  F. Guengerich,et al.  Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. , 2005, Archives of biochemistry and biophysics.

[29]  A. Kappas,et al.  7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver. , 1978, Biochemical and biophysical research communications.

[30]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[31]  G. Miller,et al.  Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. , 2001, Biochemistry.

[32]  W. Pryor Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[33]  Wei Tang,et al.  Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. , 2001, Current drug metabolism.

[34]  N. Oppenheimer,et al.  Structure and mechanism , 1989 .

[35]  James R. Halpert,et al.  Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.

[36]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[38]  J. Ladbury Application of isothermal titration calorimetry in the biological sciences: things are heating up! , 2004, BioTechniques.

[39]  D. Ballou,et al.  The use of protocatechuate dioxygenase for maintaining anaerobic conditions in biochemical experiments. , 2000, Analytical biochemistry.

[40]  F. Guengerich,et al.  Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps* , 2005, Journal of Biological Chemistry.

[41]  Slobodan Petar Rendic Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[42]  T. Baillie,et al.  A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4* , 2001, Journal of Biological Chemistry.

[43]  D. Greenblatt,et al.  Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.

[44]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Guengerich,et al.  Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.

[46]  F. Guengerich,et al.  Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6* , 2005, Journal of Biological Chemistry.

[47]  P. Hollenberg,et al.  Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. , 1998, Archives of biochemistry and biophysics.

[48]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.

[49]  S. Ekins,et al.  Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.

[50]  J. Halpert,et al.  Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.

[51]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[52]  S. Sligar,et al.  Temperature-dependent spin equilibrium of microsomal and solubilized cytochrome P-450 from rat liver. , 1979, Biochemistry.

[53]  T. Tracy,et al.  Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[54]  J. Halpert,et al.  Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[55]  S. Ekins,et al.  Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.

[56]  S. Sligar,et al.  Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. , 2005, Biochemistry.

[57]  P. Kuzmič,et al.  Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. , 1996, Analytical biochemistry.

[58]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  F. Guengerich,et al.  Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. , 1997, Biochemistry.

[60]  A. Conney,et al.  Activation of monooxygenases in human liver by 7,8‐benzoflavone , 1977, Clinical pharmacology and therapeutics.

[61]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[62]  B. Griffin,et al.  Camphor binding by Pseudomonas putida cytochrome P-450. Kinetics and thermodynamics of the reaction. , 1972, Biochemistry.

[63]  M. Shou Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. , 2002, Methods in enzymology.

[64]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[65]  D. Stewart,et al.  HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. , 1997, Toxicology letters.

[66]  J. Halpert,et al.  Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.

[67]  A. Y. Lu,et al.  Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.

[68]  Aleksandra Galetin,et al.  Modelling atypical CYP3A4 kinetics: principles and pragmatism. , 2005, Archives of biochemistry and biophysics.

[69]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[70]  J. Halpert,et al.  Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. , 2001, Chemical research in toxicology.